Quantus

Champions Oncology

CSBR-US · Nasdaq
$5.36+1.90%
2026-07-31 close

Champions Oncology — pricey right now, or cheap? And what signals are flashing today?

Open the exact grade & valuation bands with Pro →
Loading chart…
Close
AI Insight

Why these signals fired — only backtest-proven edge, told honestly

Why this signalSignal guide

Moving-average alignment
No

No active signal.

Explore this stock further
Review signal, financial and filing context in chat
Explore in chat →

Strong-buy signal — the real recordrecord · not a prediction

Not this one stock, but every strong-buy pick we actually published (US market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)

Last 30 sessions
759 picks
Next-day win rate
58.8%
Avg next-day
+0.55%
vs market
+0.45%p

Beat the market on 57.6% of picks (each pick vs its own day’s market average).

Recent publish days (next-day win rate)
07-30 27.3%07-29 30.8%07-28 11.1%07-27 50%07-24 28.6%07-23 44.4%07-22 50%07-21 60%07-20 33.3%07-17 37.5%07-16 16.7%07-15 50%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.

Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.

Valuation Grades

Relative to 759 건강관리 peers · not investment advice

Pro unlocks the composite grade, 5 factors and sector rank · ₩19,900/mo

Valuation in its own history

PER 15.83 · PBR 19.73 — own history (2000-01~) percentiles 100/100 · 34/100

PER100/100
PBR34/100

Higher indicates lower valuation relative to its history (based on earnings and book yields).

Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2025
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -7.27
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-7.27
Beneish M-Score
-2.81

No statistical flag

Sloan accrual
-8.30%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

매출 성장 + 마진 확대 + FCF 양수

Positive

매출이 +13.5% 성장하면서 영업이익률이 -14.7%에서 8.0%로 확대되었다. FCF도 양수를 유지하여 질적 성장이 확인된다.

Evidence

매출 YoY +13.5%영업이익률 -14.7%→8.0%FCF 8

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

8/9Strong

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score8/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Industry structure

USAs of 2026-08-03

건강관리

This stock is in 건강관리: revenue rank 320 of 553, share 0%.

320 / 5530%revenue share

Who dominates this industry?

  1. 1CVS Health14.1%
  2. 2McKesson13.6%
  3. 3Cigna9.4%
  4. 4Cardinal Health8.4%
  5. 5Centene6.2%
  6. 6Champions Oncology0%

Concentration

DistributedCR3 37.1%
HHI 642553 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
159.97
Direction
축소
Level
넓음
Years
22

Value lens

P90/P10
23.8
Median P/B
3.07
Level
넓음
n
467

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
8%
Interest coverage
168.6x
Return on equity (ROE)
124.6%

Operating margin −5pp

Severe margin pressure
Interest coverageBase 168.6x adverse case 63.2x
Return on equity (ROE)Base 124.6% adverse case 44.5%

Revenue −15%

Tolerable
Interest coverageBase 168.6x adverse case 143.3x
Return on equity (ROE)Base 124.6% adverse case 101.9%

Interest rate +2pp

Tolerable
Interest coverageBase 168.6x adverse case 7.6x
Return on equity (ROE)Base 124.6% adverse case 104.8%

Interest coverage limit

Current margin 7.9pp

Interest coverage limit at an operating margin of 0%

Interest expense coverage threshold

Financials at a glance

Champions Oncology's latest results and balance sheet. The bars track the last three periods.

Connections

AI-extracted related companies · for reference

Same theme
Sotio BiotechExact Sciences
🔗 See in the full market map →

Recent filings

Filings for overseas stocks are on the way. For now we cover Korean stocks only.

Like these rules? Run them automatically.

Quantus turns rules like these into backtests and automated trading — same team, free to start.

Quantus Signal · live data · not investment advice · Privacy Policy